Donor-specific anti-HLA Abs (DSA) are implicated in graft failure after Allo-SCT. [1] [2] [3] In our program, high-resolution typing for HLA-A, -B, -C, -DRB1, -DQ and -DP loci is therefore routinely performed for all recipients and stem cell donors, though some umbilical cord blood (UCB) units lack DQ or DP typing. In addition, serum samples of the recipient are tested for IgG Abs against HLA class I and class II Ags by a solid phase immunoassay (Luminex Corporation, Austin, TX, USA). We attempt to avoid graft sources that have HLA Ags or alleles targeted by these Abs. But in some cases all potential related or unrelated grafts are targeted by DSA at levels of 41000 mean florescence intensity (MFI) to one or more of the mismatched HLA alleles. For such cases we developed a strategy to decrease the DSA burden before SCT. 2 Desensitization started 4-6 weeks before transplant and involved bortezomib 1.3 mg/m 2 on days 1, 4, 8 and 11, rituximab 375 mg/m 2 weekly, i.v. Ig 1000 mg/kg, plasmapheresis (in which one plasma volume was exchanged with a 5% albumin replacement solution twice weekly), or in most cases combinations of these interventions. Plasmapheresis was continued after stem cell infusion until neutrophil engraftment in three patients with persistently high DSA levels (patients 2, 5 and 10). DSA levels were tested at baseline and at weekly intervals from the time of starting the DSA reductive therapy until engraftment.
Between May 2012 and May 2013, 10 patients met the criteria for DSA desensitization. This included five haplo/cord recipients, two double UCB recipients and three recipients of mismatched adult unrelated donor transplant. Patients and transplant characteristics are detailed in Table 1 . The baseline median DSA level was 3193 MFI (range: 1045-19 707 MFI) against one or more alleles (average two alleles). After intervention, the median DSA level was 606 MFI (range: 156-19 333 MFI). All 10 patients tolerated the treatment well with no toxicities observed.
Response to desensitization and engraftment outcomes are detailed in Table 2 . The first patient on this series had evidence of marrow hematopoiesis on day þ 14 after transplant; neutrophils peaked at 0.6 Â 10 9 /L on day þ 26 and chimerism studies showed 100% donor cells from UCB 2. This patient subsequently lost the graft, possibly in part due to CMV and HHV6 viremia. All other patients achieved reduction in DSA levels and timely and sustainable neutrophil engraftment.
Plasma cell depletion with bortezomib has been investigated to inhibit HLA Ab production in renal transplantation. 4 Bortezomib was shown to transiently eliminate DSA in 69% of patients with a median time to reemergence of DSA of 3.8 months. In the case of SCT, transient suppression of DSA production may be sufficient as plasma cells will eventually be donor derived. Similarly, rituximab has proven DSA abrogating effect. This effect is typically more delayed and takes up to 3 months. 5 I.v. Ig decreases the t 1,2 of IgG Abs by facilitating their endocytotic degradation in the endothelial cells and enhances their clearance from the serum. 6 Plasmapheresis has a proven efficacy for the extraction of IgM f DPB1 was not tested in the CBU. g DPB1 Ag mismatch, patient number 4 was mismatched at 2 Ags and patients number 8 and 9 were mismatched at 1 Ag.
and IgG macromolecules. However, as only 45% of IgG is intravascular, rapid re-equilibration of plasma levels occurs, a well-known 'rebound' phenomenon. 7 Plasmapheresis is therefore unlikely to be sufficiently effective by itself.
Arguably, the conditioning regimen could also have contributed to the decrease in DSA burden. However, patients 1, 2, 5 and 10 continued to have high DSA levels after conditioning. Furthermore, others found persistence of HLA Abs beyond conditioning in approximately half of the patients that tested positive for HLA Abs before transplantation. 8 Gladstone et al. 9 recently described a similar desensitization strategy in nine patients utilizing plasmapheresis, i.v. Ig, tacrolimus and mycophenolate mofetil starting 1-2 weeks before conditioning. Their protocol as well as ours was modified from institutional protocols utilized in organ transplant patients.
On the basis of this preliminary experience, we propose testing for DSA as early as possible before transplant, with a stepwise intervention strategy for DSA reduction. Initial treatment consists of a course of bortezomib and i.v. Ig, 6-8 weeks before transplantation with monitoring of DSA. If DSA do not decrease to o1000 MFI, the same course can be repeated augmented by plasmapheresis. Plasmapheresis appears to be quite efficacious in the short run, but often requires a catheter placement and is a burdensome procedure. We tend to reserve it for cases where transplant timing does not allow for earlier treatment or when other measures fail. Of note, plasmapheresis can also be safely utilized during conditioning and after stem cell infusion. Rituximab may cause additional immunosuppression and tends to have more delayed effects. It is unclear how much it contributed to elimination of DSA in our cases. 
